Wolters Kluwer HealthJul 12 2024 An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence , reports a placebo-controlled clinical trial in the August issue of The Journal of Urology®, an Official Journal of the American Urological Association . The journal is published in the Lippincott portfolio by Wolters Kluwer.
Duloxetine – a type of medication called a serotonin and noradrenaline reuptake inhibitor – is approved for treatment of SUI in Europe, but not in the United States or Japan. That reflects concerns about adverse effects, including a risk of nausea causing patients to discontinue treatment. Duloxetine has also been linked to a slightly increased risk of suicide or violence among patients with major depression.
In the primary endpoint, percent change from baseline to week 12 in mean frequency of SUI episodes per 24 hours, patients assigned to TAS-303 had a significant reduction. On analysis accounting for other patient characteristics , the frequency of SUI episodes decreased by about 58% with TAS-303, compared to 47% in the placebo group. Frequency of SUI episodes decreased by at least half in 65% of patients in the TAS-303 group versus 53% with placebo.